Ulcerative Colitis – Landscape & Forecast – Disease Landscape & Forecast
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara) earlier in the treatment algorithm. Additionally, the availability of Pfizer’s Xeljanz / Xeljanz XR, Bristol Myers Squibb’s Zeposia, and Gilead / Galapagos’s Jyseleca have expanded physicians’ treatment armamentarium and intensified market competition. Furthermore, the recent approvals of Eli Lilly’s Omvoh (in the United States, Europe and Japan), Pfizer’s Velsipity (in the United States and Europe), and AbbVie’s Rinvoq (in the United States and Europe) and the expected launch of several therapies with novel mechanisms of action (e.g., AbbVie’s Skyrizi, Johnson & Johnson Innovative Medicine’s Tremfya, ABX464) will drive market growth. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of and increased physician comfort prescribing less-expensive biosimilars.
QUESTIONS ANSWERED
- What are the similarities and differences in how U.S., European, and Japanese gastroenterologists treat UC?
- How do gastroenterologists perceive biosimilar agents, and what has been/will be their impact on the UC market?
- What are key opinion leaders’ (KOLs’) insights into the current treatment options for TNF-refractory UC (e.g., Xeljanz / Xeljanz XR, Entyvio, Stelara, Rinvoq, Zeposia, Jyseleca)? What factors drive their treatment decisions?
- What are KOLs’ perceptions of recently approved / key emerging therapies (e.g., Skyrizi, Tremfya, Velsipity, Omvoh), and where do they see these agents fitting into the treatment algorithm?
CONTENT HIGHLIGHTS
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 22 country-specific interviews with thought-leading gastroenterologists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of UC by country, segmented by disease activity.
Forecast: Ten-year, annualized, drug-level sales and patient share of key UC therapies through 2032, segmented by brands / generics / biosimilars, and acute and maintenance settings.
Emerging therapies: Phase 3 / preregistered: ~7 drugs; coverage of select early-phase products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast is updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Ulcerative Colitis - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market share of drug classes for ulcerative colitis: 2022
- Market share of drug classes for ulcerative colitis: 2032
- Patient share of ulcerative colitis therapies in the acute setting, by drug class: 2022-2032
- Patient share of ulcerative colitis therapies in the maintenance setting, by drug class: 2022-2032
- Ulcerative colitis SWOT analysis
- Market drivers and constraints
- Drug-class-specific trends
- Key findings
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for ulcerative colitis
- Current treatments used for ulcerative colitis
- Market events impacting the use of key current therapies for ulcerative colitis
- Aminosalicylates
- Corticosteroids
- Immunosuppressants
- TNF-alpha inhibitors
- CAM inhibitors
- JAK inhibitors
- Interleukin inhibitors
- Sphingosine-1-phosphate receptor modulators
- Medical practice
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
- Key Findings
Rohit Pareek, M.Sc., Healthcare Research and Data Analyst, Immune & Inflammatory Disorders. In his role at Clarivate, Mr. Pareek brings several years of experience in market research. Prior to joining Clarivate, he worked in a market research and consulting firm, where he oversaw projects in both the pharmaceutical and biotechnology domains. He holds a master’s degree in biotechnology from Lovely Professional University in Jalandhar, Punjab, India.
Priya Dhadwal, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. Previously, she worked with the National Aids Control Organisation in India as a research officer in HIV Sentinel Surveillance. She also worked in the healthcare financing division of the National Health Systems Resource Centre in the Ministry of Health and Family Welfare in New Delhi. She obtained her master’s degree in public health with a specialization in advanced epidemiology and biostatistics from the Post Graduate Institute of Medical Education and Research in Chandigarh, India, and her bachelor’s degree in dental surgery from HP Government Dental College in Shimla, India.